<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04781192</url>
  </required_header>
  <id_info>
    <org_study_id>IIT-2020-RegoDurva</org_study_id>
    <nct_id>NCT04781192</nct_id>
  </id_info>
  <brief_title>The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers</brief_title>
  <official_title>Phase I/II Clinical Trial of Regorafenib Plus Durvalumab (MEDI4736) in Patients With Chemo Refractory Advanced Biliary Tract Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kansas Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to measure how effective combining Durvalumab and Regorafenib&#xD;
      will be for participants with advance stage biliary track carcinoma who have received one&#xD;
      line of prior treatment&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single arm, unblinded phase I/II study with safety dose-finding in Phase I followed by efficacy determination in Phase II if maximum tolerated dose (MTD) is found in Phase I.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment related adverse events</measure>
    <time_frame>At the end of cycle 1 (each cycle is 28 days) until 30 days after end of treatment (EOT)</time_frame>
    <description>CTCAE Version 5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progressin Free Survival (PFS)</measure>
    <time_frame>At the end of each cycle (28 days) until disease progression or 2 years (end of study), whichever occurs first</time_frame>
    <description>RECIST Version 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response (OR)</measure>
    <time_frame>Start of treatment to EOT or 2 years (end of study), whichever occurs first</time_frame>
    <description>RECIST Version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Start of treatment to EOT or 2 years (end of study), whichever occurs first</time_frame>
    <description>RECIST Version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Start of treatment to EOT or 2 years (end of study), whichever occurs first</time_frame>
    <description>RECIST Version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Start of treatment to EOT or 2 years (end of study), whichever occurs first</time_frame>
    <description>RECIST Version 1.1</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Advanced Biliary Tract Cancer</condition>
  <arm_group>
    <arm_group_label>Dose Finding Regorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>We will use a 3 + 3 design with two dose levels of 80 mg and 120 mg to discover the Maximum Tolerated Dose (MTD) for regorafenib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>Intra-Venous(IV) once every 28 days (approximately every 4 weeks [q4w])</description>
    <arm_group_label>Dose Finding Regorafenib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regorafenib</intervention_name>
    <description>Oral once per day, Days 1 - 21 every 28 days</description>
    <arm_group_label>Dose Finding Regorafenib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability of patient OR Legally Authorized Representative (LAR) to understand this&#xD;
             study, and participant or LAR willingness to sign a written informed consent&#xD;
&#xD;
          -  Can swallow tablets and self-administer medication&#xD;
&#xD;
          -  Progressed on at least one line of therapy (no restrictions on type of previous&#xD;
             treatment)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status = 0 - 1&#xD;
&#xD;
          -  Measurable disease with at least 1 lesion that qualifies as a RECIST 1.1 Target Lesion&#xD;
             (TL) at baseline. Previously irradiated lesion cannot be considered as Target Lesion&#xD;
             (TL) except in cases of documented progression of the lesion since the completion of&#xD;
             radiation therapy&#xD;
&#xD;
          -  Histologically confirmed unresectable or metastatic intrahepatic/extrahepatic&#xD;
             cholangiocarcinoma or gallbladder cancer with radiographic progression, who have&#xD;
             progressed on one line of therapy / failed adjuvant therapy&#xD;
&#xD;
          -  Life expectancy of at least 3 months&#xD;
&#xD;
          -  Recovery to baseline or &lt; Grade 2 CTCAE v5.0 from toxicities related to any prior&#xD;
             treatments, unless adverse event's (AE(s)) are clinically nonsignificant and/or stable&#xD;
             on supportive therapy&#xD;
&#xD;
          -  Adequate organ function per laboratory results&#xD;
&#xD;
          -  Concomitant anticoagulation with oral anticoagulants (e.g., warfarin, direct thrombin&#xD;
             and Factor Xa inhibitors) or platelet inhibitors (e.g., clopidogrel) will be allowed&#xD;
             provided that no prior evidence of underlying abnormality in coagulation parameters&#xD;
             exists. Close monitoring of at least weekly evaluations will be performed until&#xD;
             international normalized ratio/ partial thromboplastin time (INR/PTT) is stable based&#xD;
             on a measurement that is pre-dose as defined by the local standard of care&#xD;
&#xD;
          -  Weight &gt; 30 kg (66 lbs)&#xD;
&#xD;
          -  Women of child-bearing potential and men with partners of child-bearing potential must&#xD;
             agree to use an acceptable form of contraception for the duration of study&#xD;
             participation, and for 7 months after the last study treatment&#xD;
&#xD;
          -  Men of child-bearing potential must agree not to donate sperm while on this study and&#xD;
             for 180 days (6 months) after the last dose of study treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current or anticipated use of other investigational agents while participating in&#xD;
             another clinical study, unless it is an observational (noninterventional) clinical&#xD;
             study or during the follow-up period of an interventional study&#xD;
&#xD;
          -  Psychiatric illness/social situations that would limit compliance with study&#xD;
             requirements&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Ampullary carcinoma&#xD;
&#xD;
          -  Previous treatment with regorafenib&#xD;
&#xD;
          -  Previous treatment with a programmed death 1 (PD1), programmed death-ligand (PD-L1,&#xD;
             including durvalumab), or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)&#xD;
             inhibitors, or agent directed to another co-inhibitory T cell receptor&#xD;
&#xD;
          -  Previous treatment with live vaccine within 30 days of planned start of study drugs&#xD;
             (seasonal flu vaccines that do not contain a live virus are permitted)&#xD;
&#xD;
          -  Active autoimmune disease (active defined as having autoimmune disease related&#xD;
             symptoms and detectable autoantibodies) that has required systemic treatment in the&#xD;
             past 2 years&#xD;
&#xD;
          -  Diagnosis of immunodeficiency or receiving chronic systemic steroid therapy or any&#xD;
             other form of immunosuppressive therapy within 7 days prior to the first dose of study&#xD;
             drugs. Except Intranasal, inhaled, topical steroids, or local steroid injections&#xD;
             (e.g., intra articular injection), systemic corticosteroids at physiologic doses not&#xD;
             to exceed 10 mg/day of prednisone or its equivalent, steroids as premedication for&#xD;
             hypersensitivity reactions (e.g., CT scan premedication)&#xD;
&#xD;
          -  Known history of human immunodeficiency virus (HIV) infection (HIV 1/2 antibodies).&#xD;
             Dual active hepatitis B virus (HBV) infection (HBsAg (+) and /or detectable HBV DNA)&#xD;
             and HCV infection (anti-HCV Ab(+) and detectable HCV RNA) at study entry. Single&#xD;
             active infection of HBV or HCV infection is allowed with treatment by local standards&#xD;
&#xD;
          -  Has untreated central nervous system (CNS) metastases and/or carcinomatous meningitis&#xD;
             identified either on the baseline brain imaging, unless known and treated with stable&#xD;
             for &gt;4 weeks&#xD;
&#xD;
          -  Significant acute gastrointestinal disorders with diarrhea as a major symptom e.g.,&#xD;
             Crohn's disease, malabsorption, or CTCAE Grade ≥ 2 diarrhea of any etiology&#xD;
&#xD;
          -  Receipt of the last dose of anticancer therapy (chemotherapy, immunotherapy, endocrine&#xD;
             therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal&#xD;
             antibodies) ≤ 21 days prior to the first dose of study drug&#xD;
&#xD;
          -  Any concurrent chemotherapy, investigational product (IP), biologic, or hormonal&#xD;
             therapy for cancer treatment. Concurrent use of hormonal therapy for&#xD;
             non-cancer-related conditions (e.g., hormone replacement therapy) is acceptable.&#xD;
             However, the palliative radiation to non-targeted lesions is allowed&#xD;
&#xD;
          -  Abdominal fistula, GI perforation, bowel obstruction, or intra-abdominal abscess&#xD;
             within 8 weeks before first dose. Note: Complete healing of an intra-abdominal abscess&#xD;
             must be confirmed before first dose&#xD;
&#xD;
          -  Uncontrollable ascites or pleural effusion&#xD;
&#xD;
          -  Clinically significant gross hematuria, hematemesis, or hemoptysis of &gt;0.5 tsp (2.5ml)&#xD;
             of red blood, or other history of grade 3 significant bleeding within 8 weeks&#xD;
&#xD;
          -  Any unresolved toxicity NCI CTCAE v 5.0 Grade ≥2 from previous anticancer therapy with&#xD;
             the exception of neuropathy grade 2 and below, alopecia, vitiligo, and the laboratory&#xD;
             values defined in the inclusion criteria&#xD;
&#xD;
          -  Major surgery (e.g., GI surgery, removal or biopsy of brain metastasis) within 8 weeks&#xD;
             before first dose of study treatment. Complete wound healing from major surgery must&#xD;
             have occurred 1 month before first dose and from minor surgery (e.g., simple excision,&#xD;
             tooth extraction) at least 10 days before first dose. Patients with clinically&#xD;
             relevant ongoing complications from prior surgery are not eligible&#xD;
&#xD;
          -  History of organ transplantation&#xD;
&#xD;
          -  Uncontrolled intercurrent illness, including but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, interstitial lung disease&#xD;
&#xD;
          -  Uncontrolled hypertension defined as sustained blood pressure (BP) &gt; 150 mm Hg&#xD;
             systolic or &gt; 100 mm Hg diastolic despite optimal antihypertensive treatment&#xD;
&#xD;
          -  Mean QT interval corrected for heart rate (QTcF) &gt;470 ms calculated from 3&#xD;
             electrocardiograms (ECGs) (within 15 minutes at 5 minutes apart) using Fridericia's&#xD;
             Correction&#xD;
&#xD;
          -  Stroke (including transient ischemic attack transient ischemic attack (TIA),&#xD;
             myocardial infarction (MI), or other ischemic event, or acute thromboembolic event&#xD;
             (e.g., deep venous thrombosis, pulmonary embolism) that are NOT asymptomatic with&#xD;
             local standard anti-coagulation within 4 weeks before first dose&#xD;
&#xD;
          -  History of another primary malignancy in the last 3 years except:&#xD;
&#xD;
               -  Malignancy treated with curative intent and with no known active disease ≥3 years&#xD;
                  before the first dose of IP and of low potential risk for recurrence&#xD;
&#xD;
               -  Adequately treated non-melanoma skin cancer or lentigo maligna without evidence&#xD;
                  of disease&#xD;
&#xD;
               -  Adequately treated carcinoma in situ without evidence of disease&#xD;
&#xD;
          -  Use of any Herbal remedy&#xD;
&#xD;
          -  Ongoing infection &gt;grade 2&#xD;
&#xD;
          -  Known allergy or hypersensitivity to any of the study drugs&#xD;
&#xD;
          -  Proteinuria &gt; Grade3 (&gt;3.5g/24 hours)&#xD;
&#xD;
          -  Active infection with tuberculosis (TB) (clinical evaluation that includes clinical&#xD;
             history, physical examination and radiographic findings, and TB testing in line with&#xD;
             local practice)&#xD;
&#xD;
          -  Participants with HBV infection (as characterized by positive hepatitis B surface&#xD;
             antigen [HBsAg] and/or anti-hepatitis B core antibodies (anti-HBc) with detectable HBV&#xD;
             deoxyribonucleic acid (DNA) [≥10 international units (IU)/mL or above the limit of&#xD;
             detection per local laboratory]) must receive antiviral therapy prior to randomization&#xD;
             to ensure adequate viral suppression&#xD;
&#xD;
          -  Participants must remain on antiviral therapy for the study duration and for 6 months&#xD;
             after the last dose of study treatment. Participants who test positive for anti-HBc&#xD;
             with undetectable HBV DNA (&lt;10 IU/mL or under the limit of detection per local&#xD;
             laboratory) do not require antiviral therapy unless HBV DNA exceeds 10IU/mL or reaches&#xD;
             detectable limits per local laboratory during the course of treatment&#xD;
&#xD;
          -  Patients positive for hepatitis C (HCV) antibody. EXCEPTIONS: Patients positive for&#xD;
             hepatitis C (HCV) are eligible only if polymerase chain reaction is negative for HCV&#xD;
             RNA.&#xD;
&#xD;
        Patients positive for hepatitis C (HCV) are eligible if they undergo treatment per local&#xD;
        guidelines&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raed Al-Rajabi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>KUCC Navigation</last_name>
    <phone>913-588-3671</phone>
    <email>kucc_navigation@kumc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Kansas Cancer Center - Overland Park</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Kansas Medical Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center - North</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64154</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center - Lee's Summit</name>
      <address>
        <city>Lee's Summit</city>
        <state>Missouri</state>
        <zip>64064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Kansas Medical Center</name>
      <address>
        <city>North Kansas City</city>
        <state>Missouri</state>
        <zip>64116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 25, 2021</study_first_submitted>
  <study_first_submitted_qc>March 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2021</study_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chemo-refractory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Durvalumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

